Objective
to investigate the clinical outcomes of an aspirin-free strategy (prasugrel 3.75 mg/day monotherapy) compared to DAPT (Aspirin 80-100 mg/day and prasugrel (3.75 mg/day) for PCI.
Study
physician-initiated prospective multicentre randomised trial
Population
patients with ACS or high bleeding risk
Endpoints
major bleeding (BARC 3 to 5) for superiority at 1 month MACE: cardiovascular death, MI, Stent thrombosis or ischaemic stroke for non-inferiority at 1 month
Conclusion
an aspirin free strategy of prasugrel monotherapy compared with DAPT (aspirin + prasugrel) was not superior in terms of major bleeding but was non-inferior to MACE.
Natsuaki et al. Circulation 2024;149:585-600
